August 15, 2018 12:55 PM EDTUpdated August 15, 10:05 PM
Publisher's note
China

Let's go to Chi­na: Join End­points in Shang­hai for the first US-Chi­na Bio­phar­ma In­no­va­tion & In­vest­ment Sum­mit — Oc­to­ber 22-23 #BI­IS18

Arsalan Arif

Founder

Re­cent­ly I told read­ers about a new part­ner­ship we struck in Chi­na, one that would help il­lu­mi­nate our on­line news cov­er­age of bio­phar­ma in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times